Viatris closes acquisitions of oyster point pharma and famy life sciences, establishing new viatris eye care division

Division combines oyster point pharma's eye care expertise with famy life science's phase iii-ready pipeline and lays foundation for viatris to become a  global eye care leader acquisitions have the potential to add at least $1 billion in sales by 2028 transactions showcase the power of viatris' global healthcare gateway® pittsburgh , jan. 3, 2023 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced that it has closed its acquisitions of oyster point pharma and famy life sciences to establish a new viatris eye care division. the transaction was first announced on november 7 as part of viatris' strategic update.
VTRS Ratings Summary
VTRS Quant Ranking